Skip to content

Allogene Therapeutics ALLO Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-52.3%+1.1pp-53.4%+1.0pp-54.4%+0.7pp-55.1%+4.5pp-59.6%-4.5pp
Return on assets-38.4%+1.1pp-39.6%+1.6pp-41.2%+1.2pp-42.4%+3.7pp-46.1%-2.9pp
Return on invested capital-51.3%+5.1pp-56.5%-2.8pp-53.7%+10.1pp-63.8%-5.2pp-58.6%-0.6pp
Liquidity
Current ratio9.6×+1.7×7.9×-0.3×8.2×-0.7×8.9×-0.8×9.7×+1.2×
Quick ratio9.6×+1.7×7.9×-0.3×8.2×-0.7×8.9×-0.8×9.7×+1.2×
Cash ratio1.4×-0.5×1.9×+0.4×1.5×-0.5×+0.2×1.8×-0.7×
Leverage
Debt-to-equity0.3×0.0×0.3×0.0×0.3×0.0×0.3×0.0×0.2×0.0×
Debt-to-assets0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×0.2×0.0×
Interest coverage-155.3×+39.4×-194.7×+75.0×-269.8×+155×-424.5×
Per Share
Book value per share$1.16-12.5%$1.33-6.6%$1.42-9.8%$1.57-12.1%$1.79-17.4%
Valuation
Market capitalization$711.02M+164%$307.88M+11.9%$275.13M+0.6%$273.41M-13.8%$317.21M-29.0%
Enterprise value$751.47M+146%$329.15M+5.4%$312.17M+4.8%$297.79M-15.7%$353.38M-21.8%
Price / book2.5×+1.9×1.1×+0.2×0.9×+0.1×0.8×0.0×0.8×-0.2×
Free cash flow yield-15.4%+58.2pp-48.6%+9.2pp-57.8%+5.7pp-63.5%-1.0pp-62.5%-17.5pp
Earnings yield-24.4%+69.3pp-62%+15.1pp-77.1%+9.6pp-86.6%-7.1pp-79.5%-21.9pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Allogene Therapeutics's ratios come from?
Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.